Join Growin Stock Community!

聯合4129.TW Overview

TW StockBiotech. & Medical
(No presentation for 4129)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

聯合（4129）Overall Performance

聯合（4129）AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

聯合（4129） PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

聯合（4129）Key Information

聯合（4129）Profile

United Orthopedic Corporation engages in the research, development, manufacture, and sale of orthopedic implants and surgical instruments. The company offers artificial hip joints, partial hip joints, joints for large trochanteric fracture, Moore hip prosthesis, and customized artificial hip joints for individual tumor patients; artificial knee joint, such as artificial knee replacement joint, revision knee replacement system, restricted artificial knee joints, and customized artificial knee joints for individual tumor patients; and spine products consisting of vertebral fixation devices. It also provides injury and other orthopedic products comprise orthopedic internal fixation, bone plates, bone nails, bone pins, and bone screws; OEM products, such as orthopedic internal fixation; and lamb salvage systems. In addition, the company offers orthopedic surgical equipment and its manufacturing equipment; and special metal and plastic materials, as well as imports and exports its products. It serves in Taiwan, Asia, the Americas, Europe, Africa, and Australia. The company was incorporated in 1993 and is headquartered in New Taipei City, Taiwan. United Orthopedic Corporation is a subsidiary of Chi-Yi Investment Co. Ltd.

聯合（4129）FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-
PE Ratio (TTM)
-
Forward PE
20.32
PS Ratio (TTM)
-
PB Ratio
-
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
77.24%
Net Margin
10.15%
Revenue Growth (YoY)
22.01%
Profit Growth (YoY)
20.97%
3-Year Revenue Growth
25.22%
3-Year Profit Growth
26.15%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-
PE Ratio (TTM)
-
Forward PE
20.32
PS Ratio (TTM)
-
PB Ratio
-
Price-to-FCF
-
Gross Margin
77.24%
Net Margin
10.15%
Revenue Growth (YoY)
22.01%
Profit Growth (YoY)
20.97%
3-Year Revenue Growth
25.22%
3-Year Profit Growth
26.15%
default symbol

4129

聯合

106.50D

-1.41%

(-0.01)

  • When is 4129's latest earnings report released?

    The most recent financial report for 聯合 (4129) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating 4129's short-term business performance and financial health. For the latest updates on 4129's earnings releases, visit this page regularly.

  • Where does 4129 fall in the P/E River chart?

    According to historical valuation range analysis, 聯合 (4129)'s current price-to-earnings (P/E) ratio is 17.13, placing it in the Undervalued zone on the P/E River chart. This level indicates that the market's expectations for future earnings are already reflected in the share price, with the valuation currently leaning conservative. Investors are advised to further examine the company's fundamentals and its position in the industry cycle to validate whether the valuation is justified.

  • What is the operating profit of 4129?

    According to the latest financial report, 聯合 (4129) reported an Operating Profit of 210.13M with an Operating Margin of 14.09% this period, representing a growth of 31.77% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is 4129's revenue growth?

    In the latest financial report, 聯合 (4129) announced revenue of 1.49B, with a Year-Over-Year growth rate of 31.93%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much cash does 4129 have?

    At the end of the period, 聯合 (4129) held Total Cash and Cash Equivalents of 697.02M, accounting for 0.09 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does 4129 go with three margins increasing?

    In the latest report, 聯合 (4129) achieved the “three margins increasing” benchmark, with a gross margin of 75.87%%, operating margin of 14.09%%, and net margin of 13.13%%. This demonstrates improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess 4129's profit trajectory and future growth potential.

  • Is 4129's EPS continuing to grow?

    According to the past four quarterly reports, 聯合 (4129)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at 2.01. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of 4129?

    聯合 (4129)'s Free Cash Flow (FCF) for the period is 60.2M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 8.15% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.